• Publications
  • Influence
Primary angiosarcomas of the breast
The purpose of the study was to describe the clinicopathologic characteristics and clinical outcomes of patients with primary breast angiosarcoma.
  • 103
  • 10
Small cell lung cancer.
Small cell lung cancer accounts for approximately 15% of bronchogenic carcinomas. It is the cancer most commonly associated with various paraneoplastic syndromes, including the syndrome ofExpand
  • 587
  • 7
  • Open Access
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
Importance Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array ofExpand
  • 59
  • 4
  • Open Access
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients
Abstract 201 Background: Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with relapsed multiple myeloma (MM). Between November 2007 and March 2012, we opened 6Expand
  • 37
  • 4
  • Open Access
Pathophysiology and treatment of cardiac amyloidosis
Amyloid cardiomyopathy should be suspected in any patient who presents with heart failure and preserved ejection fraction. In patients with echocardiographic evidence of ventricular thickening andExpand
  • 69
  • 3
Therapy for Relapsed Multiple Myeloma: GUIDELINES FROM THE MAYO STRATIFICATION FOR MYELOMA AND RISK‐ADAPTED THERAPY
Abstract Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease.Expand
  • 54
  • 3
Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Lenalidomide has demonstrated impressive antileukaemic effects in patients with chronic lymphocytic leukaemia (CLL). The mechanism(s) by which it mediates these effects remain unclear. Clinically,Expand
  • 59
  • 3
  • Open Access
Plasma cell leukaemia and other aggressive plasma cell malignancies
Extramedullary plasma cell cancers, such as plasma cell leukaemia (PCL) and multiple extramedullary plasmacytomas (MEP) are very aggressive malignancies. These can be primary (de‐novo) or secondaryExpand
  • 38
  • 3
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis wasExpand
  • 87
  • 2
Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia
Introduction: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the western hemisphere. Developing new therapies remains a priority as present treatment options do not offer aExpand
  • 26
  • 2